Tenaya Therapeutics adds two pharma veterans to leadership team

California, USA-based biopharma company Tenaya Therapeutics, which is focused on developing potentially curative treatments for heart disease, today announced that it has strengthened its leadership team with the appointment of Whittemore Tingley, as chief medical officer, and Kee-Hong Kim, as senior vice president of manufacturing and technical operations.

Dr Tingley, prior to joining Tenaya, served as VP clinical research, cardiology, at Cytokinetics (Nasdaq: CYTK). Before that, he spent nine years at Genentech/Roche (ROG: SIX), where he held positions of increasing responsibility.

Dr Kim has more than a decade of experience in drug manufacturing. Prior to joining Tenaya, he served as SVP, head of technical operations, at Agilis Biotherapeutics, where he was responsible for manufacturing gene therapy drug products and establishing reliable clinical and commercial supply chains. Prior to that, he was head of the gene therapy process development and global CMC lead for gene therapy at Shire, now part of Japan’s Takeda.